Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona. It binds non-selectively to melanocortin receptors (MC1R through MC5R) and has been extensively studied for its effects on melanogenesis, energy homeostasis, and reproductive physiology in preclinical research models.
Development History
Melanotan II was developed in the 1990s by Victor Hruby and colleagues at the University of Arizona as part of a systematic structure-activity relationship (SAR) program exploring melanocortin peptides. Starting from the linear 13-amino-acid α-MSH sequence (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂), researchers identified the core pharmacophore His-Phe-Arg-Trp as essential for melanocortin receptor activation.
The key innovation in MT-II design was cyclization through a lactam bridge between the side chains of aspartic acid and lysine residues flanking the core tetrapeptide. This cyclization constrains the peptide backbone into a β-turn conformation that mimics the bioactive conformation of α-MSH, resulting in dramatically increased potency (approximately 1,000-fold over linear α-MSH at MC1R) and improved enzymatic stability. The final sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂.
Melanocortin Receptor Pharmacology
The melanocortin system comprises five G protein-coupled receptors (MC1R through MC5R) with distinct tissue distributions and physiological roles. MT-II acts as a non-selective agonist at all five subtypes, which accounts for its diverse pharmacological profile in research models:
MC1R (melanocytes, immune cells): Mediates melanogenesis through cAMP/PKA signaling, activating tyrosinase and increasing eumelanin production. MC1R activation also modulates NF-κB signaling in immune cells, providing anti-inflammatory effects studied in models of UV damage and neuroinflammation.
MC3R/MC4R (hypothalamus, CNS): These receptors regulate energy homeostasis, feeding behavior, and autonomic function. MC4R activation reduces food intake and increases energy expenditure in rodent models. MT-II’s effects on these receptors have been studied in obesity and metabolic research contexts.
MC5R (exocrine glands, immune cells): Modulates sebaceous gland function and immune cell cytokine production. Less studied than other subtypes but contributes to MT-II’s broad pharmacological profile.
Melanogenesis Research
MT-II stimulates melanogenesis through MC1R-mediated activation of adenylyl cyclase, increasing intracellular cAMP levels. cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). Phospho-CREB induces transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte differentiation and pigmentation.
MITF subsequently upregulates expression of the three key melanogenic enzymes: tyrosinase, tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2/DCT). Tyrosinase catalyzes the rate-limiting step of melanin biosynthesis—oxidation of L-tyrosine to L-DOPA and subsequently to dopaquinone. The downstream pathway branches into eumelanin (brown-black) and pheomelanin (red-yellow) production depending on the availability of cysteine.
Structural Analogs and Selectivity Research
MT-II’s non-selectivity has driven development of receptor-selective analogs. Afamelanotide (Scenesse, [Nle⁴,D-Phe⁷]-α-MSH) is a linear MC1R-preferring analog that has been studied in clinical settings. PT-141 (bremelanotide) is a metabolite of MT-II (des-amino-MT-II) that retains MC3R/MC4R activity and has been investigated for different pharmacological endpoints.
Researchers have developed highly selective MC4R agonists (e.g., setmelanotide) and MC1R agonists through systematic modifications of the MT-II scaffold, including D-amino acid substitutions, N-methylation, and side-chain modifications. These selective tools have been essential for deconvoluting which receptor subtype mediates specific pharmacological observations in animal models.
Pharmacokinetics in Research Models
In rodent pharmacokinetic studies, subcutaneously administered MT-II shows rapid absorption with peak plasma concentrations achieved within 30-60 minutes. The cyclic structure confers substantial resistance to aminopeptidases and endopeptidases, with a plasma half-life of approximately 1-2 hours in mice—significantly longer than linear α-MSH (minutes). The peptide distributes to skin, hypothalamus, and adipose tissue, consistent with melanocortin receptor expression patterns.
Researchers studying MT-II pharmacokinetics should note that the peptide can be quantified in biological matrices using LC-MS/MS methods with deuterium-labeled internal standards. Mass spectrometry approaches provide the sensitivity required for accurate plasma concentration measurements at the low ng/mL levels typical of peptide therapeutics.
Research Safety Considerations
As a potent multi-receptor agonist, MT-II requires careful experimental design. Dose-response curves should be established for each model system, as EC50 values vary substantially across receptor subtypes (MC1R EC50 ≈ 0.3 nM; MC3R EC50 ≈ 3 nM; MC4R EC50 ≈ 2 nM; MC5R EC50 ≈ 6 nM). Vehicle controls and receptor-selective antagonists (e.g., SHU9119 for MC3R/MC4R) are essential for attributing effects to specific receptor subtypes.
Frequently Asked Questions
What makes Melanotan II different from Melanotan I (afamelanotide)?
Melanotan II is a cyclic heptapeptide with non-selective melanocortin receptor activity (MC1R-MC5R), while Melanotan I (afamelanotide) is a linear tridecapeptide with relative selectivity for MC1R. The cyclization in MT-II creates a more rigid structure with broader receptor affinity, while the linear structure of afamelanotide more closely resembles native α-MSH and shows preferential MC1R engagement.
How is Melanotan II typically administered in research settings?
In animal research, MT-II is most commonly administered via subcutaneous or intraperitoneal injection at doses ranging from 0.1-10 mg/kg in rodent models. Intracerebroventricular (ICV) administration is used for central nervous system studies at much lower doses (0.1-10 nmol). The peptide should be freshly reconstituted in sterile saline or PBS before each experiment session.
What analytical methods confirm Melanotan II identity and purity?
Identity is confirmed by molecular weight verification using ESI-MS or MALDI-TOF (expected [M+H]⁺ = 1024.2). Purity is assessed by reversed-phase HPLC (C18, acetonitrile/water gradient with 0.1% TFA), with research-grade material typically requiring ≥98% purity. Amino acid analysis confirms composition, and circular dichroism can verify the cyclic conformation. Always review the Certificate of Analysis.